Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M in gross proceeds from a recent private placement with two leading healthcare-focused investment funds Maintains 2021 revenue guidance range Management will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided corporate updates and reported financial result